J&J to break ground on new biologics facility in North Carolina
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru
The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding
This e-commerce platform is launched as a hyperlocal model
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
We have big plans across our B2C and B2B businesses in India and abroad
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
        Subscribe To Our Newsletter & Stay Updated